RAC3 more than a nuclear receptor coactivator: A key inhibitor of senescence that is downregulated in aging

Cell Death and Disease

Volumn 6, Issue 10, 2015, Pages

  Fernandez Larrosa P N ^a   Ruiz Grecco M ^a   Gómez, D Mengual ^b   Alvarado, C V ^a   Panelo, L C ^a   Rubio, M F ^a   Alonso, D F ^b   Gomez D E ^b   Costas, M A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; DNA; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; PROTEIN P53; RAPAMYCIN; SIRTUIN 1; STEROID RECEPTOR COACTIVATOR 3; TELOMERASE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; RAC PROTEIN; RAC3 PROTEIN, HUMAN;

AGING; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL AGING; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HEK293 CELL LINE; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL PROLIFERATION; GENE SILENCING; PHYSIOLOGY; WISTAR RAT;

AGING; ANIMALS; CELL AGING; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; HYDROGEN PEROXIDE; RAC GTP-BINDING PROTEINS; RATS, WISTAR; SIROLIMUS;

EID: 84975298256     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.218     Document Type: Article

References (60)

1. Anzick S, Kononen J, Walker R, Azorsa D, Tanner M, Guan X et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-968.
2. Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is relatedtoSRC-1andTIF2.Proc Natl Acad Sci USA 1997; 94: 8479-8484.
3. Yan J, Tsai SY, Tsai MJ. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 2006; 27: 387-394.
4. Werbajh S, Nojek I, Lanz R, Costas MA. RAC-3 is a NF-kB coactivator. FEBS Lett 2000; 485: 195-199.
5. Colo GP, Rubio MF, Nojek IM, Werbajh SE, Echeverria PC, Alvarado CV et al. The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action. Oncogene 2008; 27: 2430-2444.
6. Ma G, Ren Y, Wang K, He J. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 2011; 7: 664-672.
7. Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 2000; 89: 217-223.
8. Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 2004; 10: 6134-6142.
9. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 2002; 95: 2346-2352.
10. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65: 7976-7983.
11. Campisi J. Replicative senescence: an old lives' tale, Cell 1996; 84: 497-500.
12. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8: 1291-1297.
13. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130: 223-233.
14. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7: 3355-3361.
15. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740.
16. Martin N, Beach D, Gil J. Ageing as developmental decay: insights from p16. Trends Mol Med 2014; 20: 667-674.
17. Wu H, Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 1994; 269: 20067-20074.
18. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 8: 703-713.
19. Milas M, Yu D, Sun D, Pollock RE. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. Clin Cancer Res 1998; 4: 1573-1579.
20. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med 2014; 20: 870-880.
21. Piano A, Titorenko VI. The intricate interplay between mechanisms underlying aging and cancer. Aging Dis 2015; 6: 56-75.
22. Chen JH, Hales CN, Ozanne SE. DNA damage, cellular senescence and organismal ageing: causal or correlative, Nucleic Acids Res 2007; 35: 7417-7428.
23. Yin L, Hubbard AK, Giardina C. NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J Biol Chem 2000; 275: 36671-36675.
24. Wang N, Xu D, Sofiadis A, Hoog A, Vukojevic V, Backdahl M et al. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab 2014; 99: E1571-E1579.
25. Xu S, Cai Y, Wei Y. mTOR signaling from cellular senescence to organismal aging. Aging Dis 2014; 5: 263-273.
26. Vermeij WP, Hoeijmakers JH, Pothof J. Aging: not all DNA damage is equal. Curr Opin Genet Dev 2014; 26: 124-130.
27. Garcia-Matas S, Paul RK, Molina-Martinez P, Palacios H, Gutierrez VM, Corpas R et al. In vitro caloric restriction induces protective genes and functional rejuvenation in senescent SAMP8 astrocytes. Aging Cell 2015; 14: 334-344.
28. Russell SJ, Kahn CR. Endocrine regulation of ageing. Nat Rev Mol Cell Biol 2007; 8: 681-691.
29. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004; 306.: 2105-2108.
30. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120: 2479-2487.
31. Kim EJ, Um SJ. SIRT1: roles in aging and cancer. BMB Rep 2008; 41: 751-756.
32. Collado M, Serrano M. The senescent side of tumor suppression. Cell Cycle 2005; 4: 1722-1724.
33. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, Tasdemir E et al. Senescence, apoptosis or autophagy, When a damaged cell must decide its path-a mini-review. Gerontology 2008; 54: 92-99.
34. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120: 513-522.
35. Colo GP, Rosato RR, Grant S, Costas MA. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett 2007; 581: 5075-5081.
36. Fernandez Larrosa PN, Alvarado CV, Rubio MF, Ruiz Grecco M, Micenmacher S, Martinez-Noel GA et al. Nuclear receptor coactivator RAC3 inhibits autophagy. Cancer Sci 2012; 103: 2064-2071.
37. Chitilian JM, Thillainadesan G, Manias JL, Chang WY, Walker E, Isovic M et al. Critical components of the pluripotency network are targets for the p300/CBP interacting protein (p/CIP) in embryonic stem cells. Stem Cells 2014; 32: 204-215.
38. Percharde M, Azuara V. Essential roles for the nuclear receptor coactivator Ncoa3 in pluripotency. Cell Cycle 2012; 12: 195-196.
39. Percharde M, Lavial F, Ng JH, Kumar V, Tomaz RA, Martin N et al. Ncoa3 functions as an essential Esrrb coactivator to sustain embryonic stem cell self-renewal and reprogramming. Genes Dev 2012; 26: 2286-2298.
40. Alvarado CV, Rubio MF, Fernandez Larrosa PN, Panelo LC, Azurmendi PJ, Ruiz Grecco M et al. The levels of RAC3 expression are up regulated by TNF in the inflammatory response. FEBS Open Bio 2014; 4: 450-457.
41. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
42. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25: 6436-6446.
43. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Droge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondriaderived reactive oxygen species and the activation of NF-kappaB. Oncogene 1999; 18: 747-757.
44. Oberdoerffer P, Sinclair DA. The role of nuclear architecture in genomic instability and ageing. Nat Rev Mol Cell Biol 2007; 8: 692-702.
45. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798-1806.
46. White E, Scott WL. Eating to exit: autophagy-enabled senescence revealed. Genes Dev 2009; 23: 798-803.
47. Aravinthan A, Shannon NB. Gene expression of hepatocyte cell line (HepG2) treated with H2O2 to induce senescence relative to control untreated cells (data accessible at NCBI GEO database accession GSE47739). January 2015.
48. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010; 29: 273-283.
49. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates, EMBO Rep 2014; 15: 1139-1153.
50. Falandry C, Bonnefoy M, Freyer G, Gilson E. Biology of cancer and aging: a complex association with cellular senescence. J Clin Oncol 2014; 32: 2604-2610.
51. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003; 17: 1681-1692.
52. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai M-J. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003; 23: 7742-7755.
53. Horner SM, DeFilippis RA, Manuelidis L, DiMaio D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 2004; 78: 4063-4073.
54. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R et al. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 2004; 279: 50976-50985.
55. Bashash D, Ghaffari SH, Zaker F, Hezave K, Kazerani M, Ghavamzadeh A et al. Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. Cancer Invest 2012; 30: 57-64.
56. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-1929.
57. Vergel M, Marin JJ, Estevez P, Carnero A. Cellular senescence as a target in cancer control. J Aging Res 2010; 2011: 725365.
58. Rubio MF, Fernandez PN, Alvarado CV, Panelo LC, Grecco MR, Colo GP et al. Cyclin D1 is a NF-kappaB corepressor. Biochim Biophys Acta 2012; 1823: 1119-1131.
59. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 2003; 31: E3-E3.
60. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM et al. TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 2006; 25: 1367-1377.